Hoestdrank Broomhexine Hcl Livsane

Hoestdrank Broomhexine Hcl Livsane is a mucolytic product containing the active ingredient bromhexine hydrochloride. The preparation’s specific strength and dosage form are not disclosed, but it is intended for oral administration. Marketed within the European Union, the medication belongs to the mucolytic drug class and is used to help clear thick respiratory secretions. It is typically prescribed for patients experiencing cough with viscous sputum associated with respiratory infections.

Hoestdrank Broomhexine Hcl Livsane is indicated for conditions where thick mucus hampers normal airway clearance.

- Coughs accompanied by thick, tenacious sputum. - Acute or chronic respiratory tract infections that produce excessive mucus. - Bronchitis, including acute bronchitis, where expectoration is difficult. - Chronic obstructive pulmonary disease (COPD) exacerbations with productive cough. - Post‑viral or post‑surgical periods when mucus becomes overly viscous. - Upper respiratory tract infections such as sinusitis when mucus drainage is impaired.

Like other mucolytics, bromhexine may cause a range of adverse reactions, most of which are mild and transient. These events are generally dose‑independent and resolve after discontinuation.

Common: - Nausea or mild gastrointestinal discomfort. - Taste disturbances, often described as a bitter or metallic taste. - Mild headache or dizziness. - Skin rash or mild pruritus. - Transient abdominal cramps.

Serious: - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Severe gastrointestinal upset with vomiting or diarrhea. - Hepatic enzyme elevations indicating possible liver involvement. - Hematologic abnormalities like eosinophilia or leukopenia. - Bronchospasm or worsening respiratory symptoms.

When considering bromhexine therapy, healthcare providers should evaluate several precautionary factors to ensure safe use.

- Assess liver function, as bromhexine is metabolized hepatically. - Use with caution in patients with known hypersensitivity to bromhexine or related compounds. - Evaluate renal function in severe impairment, although renal excretion is minimal. - Monitor for worsening cough or respiratory distress, which may indicate an underlying condition. - Avoid use in individuals with active peptic ulcer disease if gastrointestinal irritation occurs. - Consider pregnancy and lactation status; data are limited, so risk‑benefit assessment is required.

Bromhexine can interact with other medicines, affecting either its efficacy or the safety profile of the co‑administered drug.

Avoid: - Concurrent use with potent CYP3A4 inhibitors, which may increase bromhexine plasma levels. - Combination with other mucolytic agents, potentially leading to excessive mucus thinning. - Strong acid‑reducing agents (e.g., proton pump inhibitors) that may alter absorption.

Use with caution: - Antitussive agents (e.g., codeine) that suppress cough, possibly reducing expectoration. - Bronchodilators, as altered mucus characteristics may affect drug delivery. - Anticoagulants, because rare reports suggest increased bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) if gastrointestinal irritation is a concern. - Antihistamines, as they may increase sedation when combined with central nervous system depressants.